You Position: Home > Paper

Aromatase inhibitors in adjuvant endocrine treatment of breast cancer: ending the debate of sequence or upfront?——interpretation of BIG 1-98 clinical trial

( views:478, downloads:208 )
Author:
No author available
Journal Title:
CANCER RESEARCH AND CLINIC
Issue:
3
DOI:
10.3760/cma.j.issn.1006-9801.2010.03.003
Key Word:
乳腺肿瘤;芳香化酶抑制剂;肿瘤辅助疗法;Breast neoplasms;Aromatase inhibitors;Neoadjuvant therapy

Abstract: The third generation of aromatase inhibitors (AI) play an important role in the adjuvant treatment of hormonal positive postmenopausal breast cancer. Compared with tamoxifen, either upfront or sequential using of Al can both significantly improve the outcome of breast cancer patients. However, there is a continuous debate of sequence or upfront usage of Al in clinical applications. With the publication result of BIG 1-98 clinical trial and interpretation of the data, we can further recognize and optimize the usage of Al in breast cancer treatment.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn